المؤلفون: Chamuleau MED; Department of Hematology, Amsterdam University Medical Center, Location VU, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands. Electronic address: m.chamuleau@amsterdamumc.nl., Stenner F; Department of Oncology, University Hospital Basel, University of Basel, Basel, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Chitu DA; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Novak U; Department of Medical Oncology, Inselspital /Bern University Hospital, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Minnema MC; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Geerts P; Department of Hematology, Isala Clinics, Zwolle, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Stevens WBC; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Zenz T; Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., van Imhoff GW; Department of Hematology, University Medical Center Groningen, Groningen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Wu KL; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Stuivenberg, Antwerp, Belgium; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Demandt AMP; Division of Hematology, Department of Internal Medicine, School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Kersten MJ; Department of Hematology, Amsterdam University Medical Center, location University of Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Terpstra WE; Department of Hematology, Amsterdam-Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Tick LW; Department of Internal Medicine, Máxima Medical Center, Eindhoven, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Deeren D; Department of Hematology, Algemeen Ziekenhuis Delta, Roeselare, Belgium; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Van Den Neste E; Department of Hematology, Cliniques universitaires Université catholique de Louvain Saint-Luc, Belgium., Gregor M; Department of Hematology, Luzerner Kantonsspital, Luzern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Veelken H; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Böhmer LH; Department of Hematology Haga Teaching Hospital, The Hague, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Caspar CB; Department of Internal Medicine, Division of Medical Oncology and Hematology, Kantonsspital Baden, Baden, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Mutsaers P; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Refos JM; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Sewsaran R; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Fu L; Pathology Facility, Amsterdam University Medical Center, Location VU, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Seefat RL; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Uyl-de Groot CA; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Netherlands., Dirnhofer S; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Van Den Brand M; Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., de Jong D; Department of Pathology, Amsterdam University Medical Center, Location VU, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Nijland M; Department of Hematology, University Medical Center Groningen, Groningen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Lugtenburg P; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

المصدر: The Lancet. Haematology [Lancet Haematol] 2023 Dec; Vol. 10 (12), pp. e966-e975. Date of Electronic Publication: 2023 Oct 31.

نوع المنشور: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Burkitt Lymphoma*/diagnosis , Burkitt Lymphoma*/drug therapy, Humans ; Male ; Female ; Etoposide ; Vincristine ; Rituximab/therapeutic use ; Methotrexate ; Cytarabine ; Cyclophosphamide/adverse effects ; Doxorubicin ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Prednisolone/therapeutic use

SCR Protocol: EPOCH protocol

المؤلفون: Issa DE; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Seefat RL; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands., Visser O; Department of Registration, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands., Zweegman S; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Lugtenburg PJ; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dinmohamed AG; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands; and.; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Chamuleau MED; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.

المصدر: Blood [Blood] 2021 May 20; Vol. 137 (20), pp. 2848-2851.

نوع المنشور: Journal Article; Comment

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Burkitt Lymphoma*/drug therapy , Burkitt Lymphoma*/epidemiology, Cyclophosphamide ; Humans ; Netherlands/epidemiology ; Vincristine